India, Feb. 3 -- Shares of BriaCell Therapeutics Corp. (BCTX) jumped over 20% on Monday morning after the clinical-stage biotechnology company announced a significant clinical response in the first patient treated with Bria-OTS, the company's novel immunotherapy for metastatic breast cancer.
BCTX is currently trading at $6.12, up $1.10 or 21.91%, on the Nasdaq. The stock opened its trading at $7.24 after closing Friday at $5.02. The stock has traded between $0.35 and $7.87 in the past 52-week period.
The company announced an unprecedented clinical response including the resolution of a lung metastasis with stable disease elsewhere. This patient is the first metastatic breast cancer (MBC) patient treated with Bria-OTS.
Bria-OTS is a perso...